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We have been active in the synthesis and characterization of tin-based antitumour compounds for
several years and we would like to summarize here the results that have already been patented(1)
and that may therefore be disclosed(2).
We synthesized some diorganotin 2,6-pyridinedicarboxylates.The dimethyltin compound has been
found inactive in vitro, whereas the di-n-butyltin, di-t-butyltin and diphenyltin compounds were
found more active than cisplatin(2).
In order to increase the water-solubility of these diorganotin derivatives, which might be a way to
increase the antitumour activity following Atassi(4), we converted them(5) into their
tetraethylammonium halide adducts.
o 0 + Et4N(*)X(’) 0 oINEt4(+)
X
The in vitro antitumour activity of the tetraethylammonium halide adducts of these diorganotin 2,6-
pyridine dicarboxylates (see table 11)(5)is not better than that of the parent molecules, even if their
solubility in protic and also in less polar solvents is considerably enhanced.
We synthesized a series of di-n-butyltin derivatives of substituted salicylic acids and tested them
against human tumour cell lines (see table 1)(2).
ID50 values in ng/mL against
Y MCF-7 WiDr Y
ID50 values in ng/mL against
MCF-7 WiDr
3-CH3 44 330 4-NH2 42 330
4-CH3 51 316 5-NH2 38 316
5-CH3 90 337 5-COOH 41 190
3-CH30 45 323 5-F 46 256
4-CH30 190 1 794 5-CI 31 280
5-CH30 29 122 5-SO3H 47 107
Cisplatin 850 624 Mitomycin C 3 17
Table 1:ID50 values (in ng/mL) of di-n-butyltin(IV) derivatives ofsubstituted salicylic acids
[YC6H3(OH)COOSnBu2]20}2, and ofcisplatin against MCF-7and WiDr
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Figure 1: X-ray structure of [diethyl(2-methylthio-3-pyridinecarboxylato) tin] oxide (6)
Because Crowe has proposed that, among the factors relating the mode of action of diorganotin
compounds R2SnX2, the organic groups R determine the potential activity(7), we prepared some
diorganotin derivatives of substituted salicylic acids with various organic groups R linked to tin (see
table 2)(2). All the compounds of this type that we prepared were less active than the corresponding
dibutyltin ones and than cisplatin.
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RR’ Y ID50 values in ng/ml against
MCF-7 WiDr
Me-n-Bu 5-CH30 488 2 784
Et2 5-CH30 2 236 4 806
n-Oct2 5-CH30 4 677 10 639
Cisplatin 850 624
Table 2:ID50 values ofselected di-organotin(IV) derivatives ofsubstituted salicylic acids,
{[Y-C6H3(OH)COOSnRR’]20}2 and of cisplatin
We also synthesized some other diorganotin 2,6-pyridinedicarboxylates, C5H3N(COO)2SnRR ’,
varying once more the groups R and R’ bound to tin (see table3). Here again, almost all the
described compounds prepared were less active than the di-n-butyltin derivative already (2)
ID50 values in ng/ml against ID50 values in ng/ml against
RR’ MCF-7 WiDr MCF-7 WiDr
n-Bu2 60 106 Ph-i-Pr 402 1 169
[p-MeO-Ph]2 4 930 15 800 Ph-n-Bu 761 3 705
Ph2 170 372 Ph-i-Bu 121 831
PhMe 2 187 3 283 Ph[PhCH2] 2 910 10 995
PhEt 918 4 046 Ph-[t-BuCH2CH2] 50 161
Ph-n-Pr 223 1 094 Ph[PhMe2CCH2] 40 106
Cisplatin 850 624
Table 3:ID50 values (in ng/ml) of selected 2,6-pyridinedicarboxylatodiorganotin(IV) derivatives
C5H3N(COO)2SnRR’ and of cisplatin
Di-n-butyltin flicarboxylates were also prepared, including some disalicylates(2) (see table 4). The
4-hydroxy-3-methoxybenzoate shows very high activities.
Several di-n-butyltin difluorobenzoates that we synthesized and characterized recently (9) exhibited
very promising in vitro antitumour activities that are reported in table 5 together with ID50 values on
some compounds currently used clinically as antitumour agents are given for comparison.
From these data, it can be deduced that all the tested compounds score slightly better than cis-
platin or etoposide against WiDr. Against MCF-7, they are even more active than doxorubicin, the
2,6-difluorobenzoate being as active as mitomycin C.
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Figure 2: X-ray crystal structure of diethyltin bis(2-methylthio-3-pyridinecarboxylate) (6)
X Y Z MCF-7 WiDr
H H 2-F 74 242
H H 3-F 63 197
H H 4-F 9O 3O9
2-OH H H 541 2 974
2-OH H 3-CH30 105 474
2-OH H 5-CH30 54 611
2-OH H 5-CI 89 319
4-OH H 3-CH30 44 82
3-OCH3 4-OCH3 5-OCH3 84 356
2-OCH3 3-OCH3 4-OCH3 93 398
2-OCH3 4-OCH3 5-OCH3 132 368
Cisplatin 850 624
Table 4:ID50 values (in ng/ml) of a series of diorganotin(IV) dicarboxylates
(X,Y,Z-C6H2COO)2SnRR’and of cisplatin (9)
216M. Gielen Metal-BasedDntgs
Molar ratio MCF-7 WiDr
Sunstituents
1:2 2,3-F2 23 283
1:2 3,5-F2 30 407
1:1 2,3-F2 9 120
1:1 2,5-F2 7 277
1:1 2,6-F2 3 174
1:1 3,5-F2 11 172
Cisplatin 850 624
Etoposide 187 624
Doxorubicin 63 31
Mitomycin C 3 17
Table 5:ID50 values (ng/mL) ofcompounds of the type (F2C6H3COO)2Sn(n-C4H9)2 (1:2
molar ratio), of the type {[(F2C6H3COO)(n-C4H9)2Sn]20}2 (1 "1 molar ratio), and of reference
compounds tested against two human tumour cell lines,
MCF-7and WiDr
We prepared also several original series of organotin molecules that are as active in vitro as
mitomycin C against MCF-7 and WiDr. The first of these, that has recently been patented(I), are
triphenyltin carboxylates(8).
X Y Z MCF-7 WiDr
H H 2-OCH3 16 15
H H 4-F 15 14
H 3-F 5-F 18 17
H 2-OH 5-CI 11 18
H 2-OH 5-NH2 14 17
H 2-OH 5-OCH3 6 15
2-OH 3-CH(CH3)2 5-CH(CH3)2 8 13
Cisplatin 850 624
Mitomycin C 3 17
Table 5: Inhibition doses ID50 in ng/mL against MCF-7 and WiDr obtained for a series of
triphenyltin benzoates, (C6H5)3Sn-OOC-C6H2XYZand for two reference compounds
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Figure 2: X-ray crystal structure of[di-n-butyl(2,6-difluorobenzoato) tin] oxide (9)
hope that have convinced you that several organotin compounds exhibit rather promising in vitro
antitumour activities again human tumour cell lines. Of course we have to wait for the in vivo test
results before claiming anything about the interest of such compounds for cancer chemotherapy.
More work has to be done in the field of the preparation and testing of organotin molecules that
might become useful antitumour drugs in the future.
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